Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma.
about
Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancerMolecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advancesTargeting EZH2 in cancerThe genetic and epigenetic alterations in human hepatocellular carcinoma: a recent updateRole of epigenetic aberrations in the development and progression of human hepatocellular carcinomaEpigenetic regulation in hepatocellular carcinoma requires long noncoding RNAsAberrant upregulation of 14-3-3σ and EZH2 expression serves as an inferior prognostic biomarker for hepatocellular carcinomaPolycomb silencers control cell fate, development and cancerLong non-coding RNA LUCAT1 is associated with poor prognosis in human non-small lung cancer and regulates cell proliferation via epigenetically repressing p21 and p57 expressionEnhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinomaEZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis.EZH2 depletion blocks the proliferation of colon cancer cells.The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients.Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.Regulation of gene expression in HBV- and HCV-related hepatocellular carcinoma: integrated GWRS and GWGS analysesp53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor.Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behaviorCoordinated regulation of polycomb group complexes through microRNAs in cancer.EZH2 as a potential target in cancer therapy.Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16.Connections between epigenetic gene silencing and human disease.Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expressionH3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinomaPolycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma.MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinomaDifferential proteomic alterations between localised and metastatic prostate cancer.Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomasCancer genetics of epigenetic genes.High expression of H3K27me3 is an independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomyTargeting EZH2 for cancer therapy: progress and perspective.Repression of E-cadherin by the polycomb group protein EZH2 in cancerEZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis.Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives.Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer.Integrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing.Polycomb group proteins are key regulators of keratinocyte functionEpigenetic regulation of skin: focus on the Polycomb complex
P2860
Q24170091-6B91B901-B851-4079-B89B-2FE6B3CFD732Q26745338-C36A0699-6B9F-4C9F-8397-86D80ED31FD0Q26769027-8EF00A5E-511F-47C1-B1F3-CE9BCC7ACB87Q27003050-E5C857A1-E34A-4BB1-B996-852C10CB1518Q27023524-9851FAC0-DCE5-4568-9563-F33695B5BC54Q28084553-2DAF80F4-D7EC-4DB9-858F-3373CB83D205Q28248070-C995922E-61E5-4FE3-BD75-88529106C965Q29619697-20935BC9-C490-4329-A535-611FA1B94568Q33709689-DD20BF23-CE4B-479C-8DA0-899A629FFD6BQ33710169-F0064200-1727-4B11-8A88-D97502038ED4Q33867376-2DD140E0-76FC-4338-AEE5-30BDE3B3D6D6Q33963796-B22D5104-3AD0-42A1-BD3C-9B4FB7823F86Q34137728-72DD14E8-E3E0-4A12-A668-FD0F2C0CB368Q34500720-B18E91A9-5CF4-4F43-A542-0F034594EAB1Q34690158-D69FB068-57FC-434F-85C0-67B0764569B7Q34769837-73D074E2-25DA-4C98-AB72-A8B126405ED0Q35042810-086549BF-2F73-4B7B-B2D7-2E3F4BF0DE55Q35116342-1F9EAD2A-E328-46D5-94EC-CD0183D3C4DBQ35167450-755C1F28-CA20-431D-96D5-88971F98E854Q35222823-822596C4-3261-48ED-83ED-96815E1DD23AQ35443085-1535DE6F-A90C-4563-9BF4-259998C74B17Q35843804-616B80D5-BD87-4A3C-8577-E67132F15DE3Q35849140-E7A9F79B-EEFD-4C22-A4DF-1EA8182CD2D4Q35876813-458DEE60-ACCA-485B-924A-E9D174DD1F0EQ36105152-91F71C17-F8E1-4183-82E9-1CA30E1E233BQ36394758-C1B1C29C-7F10-4C50-9931-5645B0E204F6Q36553042-C4D0DD1D-2461-4F40-9E6B-27B50B8C1EE8Q36562226-932206CE-7C6E-4D67-8FE6-739A3E4D0DB3Q36780903-F79FB862-69AB-4E26-B4DE-B0E1A657ED7AQ36871595-FAB4A761-DB44-4569-93D3-9E4EF8329E28Q37182805-CDF9FD4F-D19D-4475-9917-D9259F41D7EAQ37204063-C624E5E2-E1AD-4C1A-9C30-E4788C3881C2Q37212534-CAD4471F-7589-4A78-B49D-84CDAAFA2BACQ37392656-034722A4-A05E-47A3-B99D-81957DAF076CQ37446527-2BA60183-2F47-4083-AF2D-3F1896010CC8Q37581334-016F5D86-F3DE-432F-B819-2E288F1C15B6Q37629613-FA72A789-D575-4250-AC81-1CC54FB83891Q37697207-C02381BF-2ACF-4796-ABB1-FEC4FF38547EQ37810463-609D3492-5444-4C24-BBB5-1B4F8EC9522BQ37982255-9FC3D2C0-EAE6-4EE4-97C5-68DE7937B99A
P2860
Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Clinicopathological significan ...... with hepatocellular carcinoma.
@ast
Clinicopathological significan ...... with hepatocellular carcinoma.
@en
type
label
Clinicopathological significan ...... with hepatocellular carcinoma.
@ast
Clinicopathological significan ...... with hepatocellular carcinoma.
@en
prefLabel
Clinicopathological significan ...... with hepatocellular carcinoma.
@ast
Clinicopathological significan ...... with hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
Clinicopathological significan ...... with hepatocellular carcinoma.
@en
P2093
H Nagahara
K Shirouzu
S Wakiyama
T Utsunomiya
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602531
P407
P577
2005-05-01T00:00:00Z